Fairvalue-Calculator Fairvalue-Calculator
EN DE

CSPC Innovation Pharmaceutical Co (300765) Fair Value & Analysis

Consumer Defensive · CN · Market cap 33.4B CNY

Price¥24.20
Fair Value¥10.44
Upside-56.9%
Quality92/100
Evidence: Low Range ¥7.83 – ¥13.06

Analysis

CSPC Innovation Pharmaceutical Co (300765) currently trades at ¥24.20, while our model-based Fair Value estimate is ¥10.44 — implying the stock looks roughly 56.9% overvalued today. We read business quality at 92/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, functional foods, and raw materials in China and internationally. The company offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dyphylline, theobromine, pentoxifylline, and doxofylline; and health food products, such as Guoweikang Vitamin C tablets, Guoweikang B vitamin lozenges, etc. It also provides technology transfer and technical consulting services of biotechnology. The company was founded in 2006 and is headquartered in Shijiazhuang, China. CSPC Innovation Pharmaceutical Co., Ltd. is a subsidiary of CSPC NBP Pharmaceutical Co., Ltd.

Open the full interactive analysis →

Similar stocks

Nestlé S.A (NSRGF) -33% Foshan Haitian Flavouring and Food Company (603288) -22% Nestlé India Limited (NESTLEIND) -74% Grupo Bimbo, S.A. (BIMBOA) -21% Uni-President Enterprises Corp (1216) -3% Britannia Industries Limited (BRITANNIA) -32%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.